ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 95 filers reported holding ALX ONCOLOGY HLDGS INC in Q1 2021. The put-call ratio across all filers is 0.24 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $175,780 | +82.6% | 15,765 | -26.0% | 0.00% | – |
| Q1 2023 | $96,263 | -59.9% | 21,297 | +0.0% | 0.00% | – |
| Q4 2022 | $239,973 | -4.0% | 21,293 | -18.8% | 0.00% | – |
| Q3 2022 | $250,000 | +106.6% | 26,233 | +73.1% | 0.00% | – |
| Q2 2022 | $121,000 | -49.6% | 15,157 | +6.6% | 0.00% | – |
| Q1 2022 | $240,000 | -19.2% | 14,217 | +2.8% | 0.00% | – |
| Q4 2021 | $297,000 | -8.3% | 13,834 | +216.0% | 0.00% | – |
| Q3 2021 | $324,000 | +44.6% | 4,378 | +6.6% | 0.00% | – |
| Q2 2021 | $224,000 | -50.4% | 4,107 | -33.0% | 0.00% | – |
| Q1 2021 | $452,000 | -61.3% | 6,133 | -54.7% | 0.00% | -100.0% |
| Q4 2020 | $1,168,000 | – | 13,544 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $58,490,548 | 25.26% |
| Vivo Capital, LLC | 4,220,048 | $25,446,889 | 2.35% |
| MPM BioImpact LLC | 2,180,864 | $13,150,610 | 2.04% |
| Vestal Point Capital, LP | 3,600,000 | $21,708,000 | 1.62% |
| Redmile Group, LLC | 4,036,451 | $24,339,800 | 1.47% |
| Privium Fund Management B.V. | 396,966 | $2,270,646 | 0.58% |
| Paradigm Biocapital Advisors LP | 1,575,605 | $9,500,898 | 0.36% |
| Nan Fung Group Holdings Ltd | 41,950 | $252,959 | 0.27% |
| Orbimed Advisors | 1,894,462 | $11,423,606 | 0.23% |
| Affinity Asset Advisors, LLC | 100,000 | $603,000 | 0.07% |